226 related articles for article (PubMed ID: 28484215)
1. Expression proteomics study to determine metallodrug targets and optimal drug combinations.
Lee RFS; Chernobrovkin A; Rutishauser D; Allardyce CS; Hacker D; Johnsson K; Zubarev RA; Dyson PJ
Sci Rep; 2017 May; 7(1):1590. PubMed ID: 28484215
[TBL] [Abstract][Full Text] [Related]
2. Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells.
Wolters DA; Stefanopoulou M; Dyson PJ; Groessl M
Metallomics; 2012 Nov; 4(11):1185-96. PubMed ID: 23014849
[TBL] [Abstract][Full Text] [Related]
3. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
4. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
[TBL] [Abstract][Full Text] [Related]
5. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles.
Lu M; Chen F; Noy JM; Lu H; Stenzel MH
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28234423
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.
Guidi F; Modesti A; Landini I; Nobili S; Mini E; Bini L; Puglia M; Casini A; Dyson PJ; Gabbiani C; Messori L
J Inorg Biochem; 2013 Jan; 118():94-9. PubMed ID: 23142974
[TBL] [Abstract][Full Text] [Related]
8. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
[TBL] [Abstract][Full Text] [Related]
9. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.
Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH
Biomater Sci; 2019 Mar; 7(4):1652-1660. PubMed ID: 30724288
[TBL] [Abstract][Full Text] [Related]
10. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
Biancalana L; Pampaloni G; Marchetti F
Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
[TBL] [Abstract][Full Text] [Related]
11. Study of the incorporation and release of the non-conventional half-sandwich ruthenium(II) metallodrug RAPTA-C on a robust MOF.
Procopio EQ; Rojas S; Padial NM; Galli S; Masciocchi N; Linares F; Miguel D; Oltra JE; Navarro JA; Barea E
Chem Commun (Camb); 2011 Nov; 47(42):11751-3. PubMed ID: 21952589
[TBL] [Abstract][Full Text] [Related]
12. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
13. Anti-metastatic effects of RAPTA-C conjugated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids.
Lu H; Blunden BM; Scarano W; Lu M; Stenzel MH
Acta Biomater; 2016 Mar; 32():68-76. PubMed ID: 26689468
[TBL] [Abstract][Full Text] [Related]
14. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines.
Pascu GI; Hotze AC; Sanchez-Cano C; Kariuki BM; Hannon MJ
Angew Chem Int Ed Engl; 2007; 46(23):4374-8. PubMed ID: 17477461
[No Abstract] [Full Text] [Related]
15. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
Wang Z; Qian H; Yiu SM; Sun J; Zhu G
J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
[TBL] [Abstract][Full Text] [Related]
16. Cyclopentadienyl-ruthenium(II) and iron(II) organometallic compounds with carbohydrate derivative ligands as good colorectal anticancer agents.
Florindo PR; Pereira DM; Borralho PM; Rodrigues CM; Piedade MF; Fernandes AC
J Med Chem; 2015 May; 58(10):4339-47. PubMed ID: 25923600
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium(II)-arene complexes with strong fluorescence: insight into the underlying mechanism.
Zhou Q; Lei W; Chen Y; Li C; Hou Y; Zhang B; Wang X
Chemistry; 2012 Jul; 18(28):8617-21. PubMed ID: 22700010
[No Abstract] [Full Text] [Related]
18. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
19. Functional Identification of Target by Expression Proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs.
Chernobrovkin A; Marin-Vicente C; Visa N; Zubarev RA
Sci Rep; 2015 Jun; 5():11176. PubMed ID: 26052917
[TBL] [Abstract][Full Text] [Related]
20. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
